Google
DTIL Stock Analysis — PRECISION BIOSCIENCES INC (Healthcare >> Biotechnology)
DTIL FAQ
What is DTIL's P/E ratio?
PRECISION BIOSCIENCES INC (DTIL) currently trades at a P/E ratio of 8.97.
What is DTIL's ROE?
PRECISION BIOSCIENCES INC reports a Return on Equity (ROE) of -57.29%.
What is DTIL's dividend yield?
PRECISION BIOSCIENCES INC offers a dividend yield of 0.00%.
What is DTIL's Quality Score?
Our AI rates DTIL's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DTIL?
Our AI Timing Score for DTIL is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DTIL belong to?
PRECISION BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
DTIL AI Analysis Summary
Our AI summary for DTIL: PRECISION BIOSCIENCES INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 8.97, ROE of -57.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.99
Price
-0.01
(-0.14%)
Day Change
|
|
|---|
DTIL, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.99 |
| PBV / Sector |
2.37 / 5.20
|
| Earning Per Share | -1.69 |
| PE / Sector |
8.97 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.04 / 1.22
|
| Average 1M Daily Value |
3.75 M
GREAT
|
| Average 1W Daily Value |
1.64 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
50% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:44 |
| Symbol | DTIL |
| Name | PRECISION BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 25.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 180.62 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 302 East Pettigrew St., Durham, NC, United States, 27701
Phone: 919 314 5512
Website: https://precisionbiosciences.com
Employees: 66
Sector: Healthcare >> Biotechnology
Description: Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap